Slide 1: Electromed, Inc. Investor Presentation
Electromed, Inc. Investor Presentation August 26, 2025 NYSE American: ELMD Innovation Leader in Airway Clearance Technologies Investor Presentation | 1
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation constitute forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “anticipate,” “believe,” “committed,” “continue,” “e
Slide 3: Electromed – Who We Are
Electromed – Who We Are Electromed, Inc. is a Key Stats: growing medical device company Headquarters: Ticker: Established: focused on airway New Prague, MN ELMD 1992 management to help people around the world breathe better, Annual Revenue: Market Cap: Share Count: $64.0M $187M 8.5M stay healthier,
Slide 4: Electromed Highlights
Electromed Highlights 33% Operating Income CAGR* $64.0 » Growing and profitable medical technology company $54.7 » A leader in the large and expanding airway clearance $48.1 market $41.7 » The SmartVest® Airway Clearance System’s $35.8 High Frequency Chest Wall Oscillation (“HFCWO”) technology suppo
Slide 5: What is Bronchiectasis (BE)?
What is Bronchiectasis (BE)? » Irreversible lung condition characterized by abnormal widening of one or more of the bronchi (airways) » Repeated episodes of pulmonary inflammation and infection leads to mucus accumulating in the airways » Mean prevalence of bronchiectasis in patients with COPD is 54
Slide 6: U.S. Market: Large, Growing, Underpenetrated
U.S. Market: Large, Growing, Underpenetrated Estimated HFCWO bronchiectasis ~148K Bronchiectasis HFCWO penetration, treated population3 HFCWO ADOPTED3 penetration ~16%3 ~923K Diagnosed BE population Estimated Net Bronchiectasis U.S. BE Diagnosed1 prevalence, DIAGNOSED1 growing at ~12% annually1 Esti
Slide 7: How is Bronchiectasis Treated?
How is Bronchiectasis Treated? Antibiotics, Anti-Inflammatories, Airway Clearance Investor Presentation | 7
Slide 8: How is Bronchiectasis Treated?
How is Bronchiectasis Treated? HFCWO Therapy – Mimics Manual CPT Investor Presentation | 8
Slide 9: SmartVest Clearway
SmartVest Clearway® HFCWO Designed with the Patient in Mind An Enhanced Patient Experience Sleek and light weight generator Intuitive user interface for better patient adherence More portable and easier for travel SmartVest® has a well-established reimbursement code from CMS – E0483; We estimate we
Slide 10: SmartNotes Patient Progress Report
SmartNotes™ Patient Progress Report Patient Outcomes and Treatment Progress to Physicians SmartNotes combine patient Quality of Life and Therapy Utilization data to provide physicians with extended views into disease management » TeleRespiratory Services: A team of Respiratory Therapists stay connec
Slide 11: Clinical Evidence
Clinical Evidence Electromed has Published Studies Showing Effectiveness of HFCWO to Treat Bronchiectasis Therapy with Therapy with SmartVest® HFCWO demonstrated key significantly decreased health outcomes improved exacerbations requiring in post- compared to pre- hospitalization, antibiotic index p
Slide 12: Direct-to-Patient Model
Direct-to-Patient Model Drives Attractive Margin Profile Traditional Medical Manufacturer $ DME $ Patient Equipment Channel vs. Direct-to-Patient Electromed $ Patient Distribution (Electromed) Company expects gross margins in the mid-70s and improving with the SmartVest® Clearway® Investor Presenta
Slide 13: Net Revenue Breakdown - $64.0M (TTM ended 6/30/2025)
Net Revenue Breakdown - $64.0M (TTM ended 6/30/2025) By Setting Homecare By Homecare Qualified Payer Referral Volume 1% 5% 2% 2% 20% 46% 3% 52% 75% 94% Home Care1 Medicare Bronchiectasis Hospitals Commercial/Other2 Cystic Fibrosis Other Medicaid Neuromuscular Other 1.Includes $2.9 million from home
Slide 14: Growth Strategy
Growth Strategy How Will Electromed Increase Market Share? Continued sales force expansion along with complementary infrastructure investments Increase brand awareness and revenue with direct-to-consumer and physician marketing Market development to improve diagnosis rates and evidence to support th
Slide 15: Long-Term Objectives
Long-Term Objectives Electromed is committed to delivering long-term profitable growth Double-digit Revenue Growth Increase market share Deeper penetration of current SmartVest prescribers Operating Margin Improvement Operating leverage as revenue increases Investor Presentation | 15
Slide 16: Capital Allocation Strategy
Capital Allocation Strategy Proven execution against our priorities 2025 Execution Capital Allocation New CRM & CAPEX investments Sales rep expansion Organic Business Growth Market development Triple Down on BE campaign Product enhancements Generate Free Cash Flow Potential Strategic Retur
Slide 17: Why Invest?
Why Invest? Large, expanding Clinically proven Broad Consistent High gross chronic technology payor coverage double-digit margins, lung diseases organic robust cash flow market revenue growth and expanding operating leverage Investor Presentation | 17
Slide 18: Performance vs. Russell Medical Equipment Index
Performance vs. Russell Medical Equipment Index (TTM and as of 6/30/2025 Results) RUS Metric ELMD ME Sales Growth 17.0% > 11.7% Gross Margin 78.1% > 51.6% Operating Margin 15.1% > (3.5%) Investor Presentation | 18
Slide 19: Jim Cunniff, President & CEO; Brad Nagel, CFO
Jim Cunniff, President & CEO (952) 758-9299 Mike Cavanaugh jcunniff@Electromed.com (617) 877-8641 mike.cavanaugh@icrhealthcare.com Brad Nagel, CFO (952) 758-9299 bnagel@Electromed.com Investor Presentation | 19
Slide 20: APPENDIX
APPENDIX Investor Presentation | 20
Slide 21: Financial Highlights
Financial Highlights Financial Summary Year Ended (in $ millions, except shares amounts) June 30, 2024 June 30, 2025 Revenues $54.7 $64.0 Gross Profit $41.7 $50.0 Gross margin 76% 78% Operating income $6.6 $9.7 Operating margin 12% 15% Net income $5.2 $7.5 Diluted EPS $0.58 $0.85 Diluted Shares 8,86